News

Deal Announcements

Argos Therapeutics Raises $35 Million Series C

Thursday, April 24, 2008 5:54:00 AM PDT | VentureDeal Staff
DURHAM, NC -- Biotechnology company Argos Therapeutics, Inc. announced the close of its third venture capital funding, receiving $35.2 million in new investment from a syndicate of firms.

Argos is developing a new generation of cancer and infectious disease therapeutics that "trains" the human immune system to recognize and attack the disease.

TVM Capital led the round, which included the Morningside Group, Forbion Capital Partners, Intersouth Partners, The Aurora Funds, GeneChem and others.

Proceeds from the financing will be used to fund Phase II of the company's Arcelis immunotherapy candidate trials.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1